Hyaluronic acid-heparin conjugated decellularized human great saphenous vein patches decrease neointimal thickness
Bai, H.; Wang, Z.; Li, M.; Liu, Y.; Wang, W.; Sun, P.; Wei, S.; Wang, Z.; Li, J.'a.; Dardik, A.
Journal of Biomedical Materials Research. Part B Applied Biomaterials 108(6): 2417-2425
2020
ISSN/ISBN: 1552-4981 PMID: 32022402 DOI: 10.1002/jbm.b.34574
Accession: 069784270
Although the science of implantable materials has advanced therapeutic options in vascular surgery, graft failure is still a problem in need of a durable solution. With the development of coating and decellularization techniques, coated prosthetic grafts have become an option; however, whether decellularized human saphenous vein can be conjugated and implanted is not known. Human great saphenous vein (GSV) was harvested and decellularized and hyaluronic acid (HA)-heparin was conjugated to the GSV; water contact angles (WCA), morphology, and sulfur element change were measured before and after heparin bonding. GSV patches were implanted into the rat inferior vena cava and aorta; patches were harvested (Day 14) and analyzed. HA-heparin was successfully conjugated to the decellularized human GSV with altered morphology and reduced WCA. The HA-heparin coated decellularized GSV patch was anti-thrombotic in vitro, and significantly decreased neointimal thickness both in patch venoplasty and angioplasty in a rat model. Both CD90 and nestin positive cells participated in neointima formation. These data show that HA-heparin coated human GSV patches decrease neointimal thickness when used both in venoplasty and arterioplasty. Tissue engineered decellularized human GSV is a promising vascular prosthesis.